Holen Sie sich die Stockscreener-App
22.50
3.76%
0.825
Schlusskurs vom Vortag:
$21.68
Offen:
$21.35
24-Stunden-Volumen:
230.98K
Relative Volume:
0.91
Marktkapitalisierung:
$719.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.24M
KGV:
-10.02
EPS:
-2.2449
Netto-Cashflow:
$-51.79M
1W Leistung:
+12.59%
1M Leistung:
+8.36%
6M Leistung:
+243.98%
1J Leistung:
+1,150%
1-Tages-Spanne:
$21.00
$22.60
1-Wochen-Bereich:
$19.49
$23.87
52-Wochen-Spanne:
$1.64
$25.17
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
22.51 | 692.58M | 0 | -63.24M | -51.79M | -2.2449 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-11-17 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-23 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-09-03 | Eingeleitet | Wedbush | Outperform |
| 2024-02-27 | Eingeleitet | Jefferies | Buy |
| 2024-02-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-27 | Eingeleitet | Stifel | Buy |
| 2024-02-27 | Eingeleitet | TD Cowen | Outperform |
| 2024-02-27 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
ANRO stock on investors’ radar after failed schizophrenia study results - MSN
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO) - theglobeandmail.com
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Sahm
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss - MSN
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience Price Target Cut to $21.00/Share From $22.00 by Wedbush - Moomoo
Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - marketscreener.com
Alto Neuroscience (ANRO) Receives Reiterated "Buy" Rating by HC Wainwright & Co. | ANRO Stock News - GuruFocus
Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird - MarketBeat
HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade - MarketBeat
Wedbush Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $21.00 - MarketBeat
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $35 - Moomoo
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $44 - Moomoo
A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $30 to $44 - Moomoo
Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital - MarketBeat
Alto Neuroscience Announces Phase 2 Results for ALTO-101, Prioritizes ALTO-207 in Treatment-Resistant Depression Pipeline 123 - Minichart
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Conc - The National Law Review
Alto Neuroscience stock falls after trial misses primary endpoint By Investing.com - Investing.com Canada
Chardan Capital Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Alto Neuroscience’s ALTO-101 misses primary endpoint in trial By Investing.com - za.investing.com
Stocks to Watch: Franklin Covey, Penguin Solutions, Alto Neuroscience - Moomoo
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - stocktwits.com
Alto Shifts Focus to ALTO-207 After ALTO-101 Data - tipranks.com
After the highly anticipated study on cognitive function in schizophrenia failed to meet its primary clinical endpoint, biopharmaceutical company Alto Neuroscience Inc (ANRO) suffered a sharp decline in after-hours trading, plunging by 18.8% and closing at $19 - Bitget
Alto Neuroscience reports topline data from phase 2 proof-of-concept study of Alto-101 and highlights pipeline advancements - marketscreener.com
Alto Neuroscience Inc announced the successful development of an improved once-daily extended-release oral formulation of Alto-101. - Bitget
Alto Neuroscience's Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - marketscreener.com
Alto Neuros Reports Topline Phase 2 Data for ALTO-101; ALTO-207 Phase 2b on Track, $275M Cash - TradingView
Alto Neuroscience (NYSE: ANRO) shifts focus to ALTO-207 after ALTO-101 miss - Stock Titan
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Eagle-Tribune
Alto Neuroscience (NYSE:ANRO) Trading 9.1% HigherHere's Why - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Alto Neuroscience (ANRO) price target increased by 15.20% to 36.72 - MSN
[DEF 14A] Alto Neuroscience, Inc. Definitive Proxy Statement - Stock Titan
Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts & US$120M Financing - Streetwise Reports
Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track - Streetwise Reports
Alto Plunges 8.96% Despite Bullish Technicals - Bitget
Alto Neuroscience (NYSE:ANRO) Trading Down 5.5%What's Next? - MarketBeat
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement - Yahoo Finance
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207 - Investing News Network
A $120M drug-development raise leads NYSE's premarket lineup - Stock Titan
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Pharmaceuticals Select Industry Index - MarketScreener
If You Invested $1,000 in Alto Neuroscienc (ANRO) - Stock Titan
Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):